Physician
Hematology
Dr. Sheeba K. Thomas, MD
|
|
Give Review
Sheeba K. Thomas is an expert in the field of Hematology. She went to Boston University School of Medicine. Boston University School of Medicine has a rank of 30 in research and a 52 in primary care Sheeba Thomas is a published doctor. She has 25 papers published. The most current publication "Measuring therapy-induced peripheral neuropathy: preliminary development and validation of the Treatment-induced Neuropathy Assessment Scale (TNAS)." She accepts Medicare.
Publications
- Measuring therapy-induced peripheral neuropathy: preliminary development and validation of the Treatment-induced Neuropathy Assessment Scale (TNAS).
- Targeting the Spleen Tyrosine Kinase with Fostamatinib as a Strategy Against Waldenström's Macroglobulinemia.
- Subclinical Peripheral Neuropathy in Patients With Multiple Myeloma Before Chemotherapy Is Correlated With Decreased Fingertip Innervation Density.
- Evidence of a role for CD44 and Cell adhesion in mediating resistance to lenalidomide in multiple myeloma: therapeutic implications.
- Durable responses with autologous hematopoietic SCT in patients with POEMS syndrome.
- Evaluation of the QTc prolongation potential of a monoclonal antibody, siltuximab, in patients with monoclonal gammopathy of undetermined significance, smoldering mult...
- Change in patient-reported outcomes during the first year post-diagnosis of multiple myeloma.
- Oral lenalidomide with rituximab in relapsed or refractory diffuse large Cell, follicular and transformed lymphoma: a phase II clinical trial.
- Subclinical pretreatment sensory deficits appear to predict the development of pain and numbness in patients with multiple myeloma undergoing chemotherapy.
- A phase 2 multicentre study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma.
- Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in pre-clinical models of multiple myeloma.
- Curability of multiple myeloma.
- Lymphoma Vaccine Therapy: Next Steps After a Positive, Controlled Phase III Clinical Trial.
- Changes in Pain and Other Symptoms in Patients With Painful Multiple Myeloma-Related Vertebral Fracture Treated With Kyphoplasty or Vertebroplasty.
- Predictors of prolonged survival after allogeneic hematopoietic stem Cell transplantation for multiple myeloma.
- Feasibility of autologous hematopoietic stem Cell transplant in patients aged â¥70 years with multiple myeloma.
- Solitary plasmacytomas: Outcome and prognostic factors after definitive radiation therapy.
- Effect of long-term storage in TRIzol on microarray-based gene expression profiling.
- Novel agents for relapsed and/or refractory multiple myeloma.
- Asian ethnicity as a predictor of response in patients with non-small-Cell lung cancer treated with gefitinib on an expanded access program.
- Electroacupuncture for thalidomide/bortezomib-induced peripheral neuropathy in multiple myeloma: a feasibility study.
- Role of combination bortezomib and pegylated liposomal doxorubicin in the management of relapsed and/or refractory multiple myeloma.
- Lenalidomide in multiple myeloma.
- Blockade of interleukin-6 signalling with siltuximab enhances melphalan cytotoxicity in preclinical models of multiple myeloma.
Schools
Boston Univ Sch Of Med
Procedures Preformed
- Cardiac MRI (Magnetic Resonance Imaging) of Heart or Chest
- HPC Transplantation (Stem Cell Transplant)
- Plasmapheresis
- Prostate Cancer Screening Exam (DRE)
- View All
Conditions Treated
- Acute Leukemia
- Anemia
- Basal Cell Carcinoma
- Bile Duct Cancer
- View All
Doctors Specialties
- Hematology
- Medical Oncology
- Oncology
Accepted Insurances
Education
-
University of Texas Health Science Center -
Temple University Hospital -
Boston University School of Medicine
Hospital
-
University of Texas M.D. Anderson Cancer Center
Drug Facts
| NPI NUMBER | 1952483380 | |
| NPPES Provider LastName | THOMAS | |
| NPPES Provider FirstName | SHEEBA | |
| NPPES Provider ZIPCode | 770304009 | |
| NPPES Provider State | TX | |
| Specialty Description | Internal Medicine | |
| Total Claim Count | 1218.0 | |
| Distinct Opioid Count | 2.0 | |
| Opioid Claim Count | 54.0 | |
| Percent Opioid Claims | 4.43 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1952483380 |
| Last Name Of The Provider | THOMAS |
| First Name Of The Provider | SHEEBA |
| View All |
Similar Doctors
|
|
Dr. Karen L. Cottingham, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Shirisha Reddy, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Roy B. Jones, MD |
|
|
Dr. Kenneth K. Wu, MD |
|
|
Dr. Michael J. Overman, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Ulas D. Bayraktar, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Gheath Al-Atrash, DO
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. George Carrum, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Kristy L. Richards, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Vahid Afsharkharghan, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Richard T. Lee, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. George R. Blumenschein Jr., MD |
|
|
Dr. Ming-Sheng Lee, MD |
|
|
Dr. Jeffrey J. Molldrem, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Benita P. Williams |
|
|
Dr. Raymond Alexanian, MD
This Doctor is OpenDoctor Recommended.
|